We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Israeli Scientists to Announce Development of Coronavirus Vaccine

By LabMedica International staff writers
Posted on 16 Mar 2020
Over 50 experienced PhD scientists from the Israel Institute for Biological research (IIBR; Ness-Ziona, Israel) are working to produce a vaccine and antibody for the novel coronavirus.

IIBR was established in 1952 as a governmental research institute, founded by a group of scientists from the IDF Science Corps and from academic organizations. More...
Over the years, IIBR has been engaged in R&D in the fields of biology, chemistry, and environmental sciences. Since 1995, it has operated as a government-affiliated unit that research all areas of defense against chemical and biological weapons, including the operation of national laboratories for detection and identification of such threats. IIBR has now been assigned by the Israeli Prime Minister Mr. Benjamin Netanyahu to produce a vaccine and antibody for the novel coronavirus.

According to reports, scientists at IIBR have had a significant breakthrough in understanding the biological mechanism and qualities of the coronavirus and are expected to announce the completion of the development of a vaccine for COVID-19. However, a number of pre-clinical and clinical trials will have to be conducted for months before the vaccination can be deemed as effective or safe to use. Nevertheless, in view of the global emergency over the coronavirus pandemic, the trials could be accelerated to vaccinate a majority of the people who are at the highest risk of contracting the coronavirus.

Related Links:
The Israel Institute for Biological research (IIBR)


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Complement C7 was identified through multi-omics analysis, validated across MASLD cohorts, localized to hepatic stellate cell-rich fibrotic regions, and linked to extracellular matrix remodeling. (Image Credit: Dr. Takefumi Kimura from Shinshu University, Japan)

Multi-Omics Study Identifies Blood Marker for MASLD Progression

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cause of liver-related morbidity and mortality worldwide. As MASLD progresses, fibrosis and liver-related events, including hepatocellular... Read more

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.